Are drug-eluting stents cost-effective when compared with bare-metal stents in a real-world setting?
Moussa
Issam
I
Endovascular Services at the Center for Interventional and Vascular Therapy, Columbia University Medical Center and NY Presbyterian Hospital, New York, NY 10032, USA. imoussa@crf.org
D000328:Adult; D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000295:instrumentation* / Q000379:methods; D017023:Coronary Angiography; D003327:Coronary Disease / Q000000981:diagnostic imaging / Q000401:mortality / Q000628:therapy*; D003362:Cost-Benefit Analysis; D016503:Drug Delivery Systems; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008670:Metals; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage*; D011336:Probability; D011474:Prosthesis Design; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D020123:Sirolimus / Q000008:administration & dosage*; D015607:Stents / Q000191:economics*; D015996:Survival Rate; D016896:Treatment Outcome
D008670:Metals; D017239:Paclitaxel; D020123:Sirolimus